Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a 1-Month pill course stop TB in schools?

NCT ID NCT06022146

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests whether a 4-week course of two TB drugs works as well as the standard 3-month course to prevent active TB in students and staff who have been exposed. About 3,520 people from schools will take either the short or standard regimen. The goal is to see if the shorter option is easier to complete and just as effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isoniazid and rifapentine
What this could lead to
If successful, this could offer a shorter, easier TB prevention option for teens and young adults, potentially increasing the number of people who complete treatment.
What could go wrong
This is a large phase 3 trial, but the shorter regimen may still cause side effects or be less effective than the standard 3-month course. Results may not apply outside school settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 3,520 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥13 years and body weight ≥ 30 kg; 2. School-registered individuals including: * Currently attending junior / senior high school or university students; * School staff members; 3. Close contacts of active pulmonary TB index cases (confirmed or clinically diagnosed) within the school, defined by meeting both of the following: * Teachers/students sharing the same classroom or dormitory with the index case; * Exposure history: Prolonged sharing of enclosed space (\>4 hours total within 1 week) with the index case; 4. Confirmed LTBI status through screening; 5. Voluntary participation with signed informed consent form (for adults ≥18 years); 6. Parental / guardian consent and co-signed informed consent form (for minors aged 13-17 years). Exclusion Criteria: 1. Current active TB disease (clinically or bacteriologically confirmed); 2. Documented isoniazid/rifampicin resistance in the corresponding M. tuberculosis strain from the index case; 3. Self-reported use of rifamycins (e.g., rifampicin, rifapentine) or isoniazid for \>14 consecutive days within the past 2 years; 4. Prior completion of full-course of treatment for ATB or LTBI; 5. Hypersensitivity or intolerance to rifamycins (rifapentine / rifampicin) or isoniazid; 6. HIV positive serostatus or AIDS patients; 7. History of viral hepatitis (e.g., chronic hepatitis B, chronic hepatitis C) or liver cirrhosis; 8. Liver dysfunction (TBil\>2.5mg/dL \[43umol/L\] or ALT / AST\>2ULN) or renal dysfunction. 9. Current receiving immunosuppressive therapy or biological agents. 10. Hematologic disorders with either PLT\<50×109/L or WBC\<3.0×109/L. 11. Other conditions deemed unsuitable for TPT by investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Latent tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    66 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 3rd People's Hospital of Bijie

    RECRUITING

    Bijie, China

  • Chinese Medicine Hospital of Qingzhen

    RECRUITING

    Guiyang, China

  • Dalian Public Health Clinical Center

    RECRUITING

    Dalian, Liaoning, China

  • First People's Hospital of Fuquan

    RECRUITING

    Qiannan, Guizhou, China

  • First People's Hospital of Kaili

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • Guiyang Public Health Treatment Center

    RECRUITING

    Guiyang, Guizhou, China

  • Guizhou Aerospace Hospital

    RECRUITING

    Zunyi, Guizhou, China

  • Huashan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

  • Liuzhi Special District

    RECRUITING

    Liupanshui, Guizhou, China

  • People's Hospital of Baiyun District

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Bozhou District

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Cengong

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou, China

  • People's Hospital of Changshun

    RECRUITING

    Qiannan, China

  • People's Hospital of Chishui

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Congjiang

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Prefecture, Guizhou, China

  • People's Hospital of Dafang Town

    RECRUITING

    Bijie, China

  • People's Hospital of Danzhai

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Daozhen Klau and Hmong autonomous county

    RECRUITING

    Daozhen Klau and Hmong Autonomous County in Zun'yi, Guizhou, China

  • People's Hospital of Fenggang

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Guanling

    RECRUITING

    Anshun, Guizhou, China

  • People's Hospital of Hezhang

    RECRUITING

    Bijie, Guizhou, China

  • People's Hospital of Honghuagang District

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Huangping

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Huaxi District

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Jianhe

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Jinping

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Kaiyang

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Leishan

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Libo

    RECRUITING

    Qiannan, Guizhou, China

  • People's Hospital of Liping

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Luodian

    RECRUITING

    Qiannan, Guizhou, China

  • People's Hospital of Majiang

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, China

  • People's Hospital of Meitan

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Nayong

    RECRUITING

    Bijie, China

  • People's Hospital of Panzhou

    RECRUITING

    Liupanshui, Guizhou, China

  • People's Hospital of Pingba District

    RECRUITING

    Anshun, Guizhou, China

  • People's Hospital of Puding

    RECRUITING

    Anshun, Guizhou, China

  • People's Hospital of Qianxi

    RECRUITING

    Bijie, Guizhou, China

  • People's Hospital of Qianxi

    RECRUITING

    Bijie, Guizhou, China

  • People's Hospital of Renhuai

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Rongjiang

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Sansui

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Shibing

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Shuicheng District, Liupanshui City

    RECRUITING

    Liupanshui, Guizhou, China

  • People's Hospital of Suiyang

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Taijiang

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, China

  • People's Hospital of Tianzhu

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Tongzi

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Wanshan District

    RECRUITING

    Tongren, Guizhou, China

  • People's Hospital of Weining

    RECRUITING

    Bijie, Guizhou, China

  • People's Hospital of Wuchuan Klau and Hmong autonomous county

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Wudang District

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Xifeng

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Xishui

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Xiuwen

    RECRUITING

    Guiyang, Guizhou, China

  • People's Hospital of Xixiu District

    RECRUITING

    Anshun, Guizhou, China

  • People's Hospital of Yuqing

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Zhengan

    RECRUITING

    Zunyi, Guizhou, China

  • People's Hospital of Zhenning

    RECRUITING

    Anshun, Guizhou, China

  • People's Hospital of Zhenyuan

    RECRUITING

    Qiandongnan Miao and Dong Autonomous Region, Guizhou, China

  • People's Hospital of Zhijin

    RECRUITING

    Bijie, Guizhou, China

  • People's Hospital of Ziyun

    RECRUITING

    Anshun, Guiyang, China

  • Second People's Hospital of Liupanshui City

    RECRUITING

    Liupanshui, Guizhou, China

  • Third People's Hospital of Liupanshui

    RECRUITING

    Liupanshui, Guizhou, China

  • Zunyi Infectious Disease Hospital

    RECRUITING

    Zunyi, Guizhou, China

  • Zunyi Infectious Disease Hospital

    RECRUITING

    Zunyi, Guizhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.